Recent searches
Search options
#Safety and #efficacy of inhaled IBIO123 {#mAbs} for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial, Lancet Infect Dis., https://doi.org/10.1016/S1473-3099(23)00393-6 #research #covid19 #SARS_CoV_2 #medicine #science
''Inhalation of IBIO123 was safe. Despite the lack of significant reduction of viral load at day 5, #treatment with IBIO123 resulted in a higher proportion of participants with complete resolution of respiratory #symptoms at day 8. This study supports further clinical research on inhaled monoclonal antibodies in COVID-19 and respiratory diseases in general.''